Donor Lymphocyte Infusion (DLI)

BIOLOGICAL13 trials

Sponsors

Sidney Kimmel Cancer Center at Thomas Jefferson University, M.D. Anderson Cancer Center, National Cancer Institute (NCI), Northwell Health, Masonic Cancer Center, University of Minnesota

Conditions

ALLAMLAcute LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaAcute Myelogenous LeukemiaAcute Myeloid LeukemiaAdult Acute Lymphoblastic Leukemia in Remission

Phase 1

A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative

CompletedNCT00429143

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityHematologic Malignancies

Start: 2006-01-31End: 2010-06-30Updated: 2025-05-04

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

TerminatedNCT01350258

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityAcute Leukemia, Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy, Hematologic Malignancies +4

Start: 2011-04-30End: 2012-08-31Updated: 2025-05-31

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

TerminatedNCT01875237

M.D. Anderson Cancer CenterLeukemia, Myeloma, Myeloproliferative Diseases

Start: 2013-12-27End: 2017-03-07Updated: 2019-07-16

Phase 2

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

TerminatedNCT00499889

M.D. Anderson Cancer CenterLeukemia

Start: 2003-02-28End: 2009-11-30Updated: 2012-04-23

Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation

TerminatedNCT00984165

National Cancer Institute (NCI)Chronic Lymphocytic Leukemias, Hodgkin's Lymphoma, Multiple Myeloma With Plasmacytoma +1

Start: 2010-01-19End: 2013-01-31Updated: 2018-05-02

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

TerminatedNCT01174082

M.D. Anderson Cancer CenterMyeloma

Start: 2010-07-20End: 2017-02-23Updated: 2018-06-01

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

CompletedNCT01341301

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityHematologic Malignancy

Start: 2010-05-31End: 2014-08-07Updated: 2025-04-30

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

CompletedNCT01350245

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia +7

Start: 2010-07-31End: 2014-05-31Updated: 2025-05-16

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

CompletedNCT01384513

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityAdult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities +44

Start: 2011-08-04End: 2022-11-16Updated: 2022-11-17

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

TerminatedNCT01532635

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityAcute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, ALL +9

Start: 2012-03-31End: 2013-05-31Updated: 2025-05-04

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

CompletedNCT01982682

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityHematopoietic/Lymphoid Cancer

Start: 2013-11-04End: 2017-03-27Updated: 2025-04-30

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

CompletedNCT04055844

Masonic Cancer Center, University of MinnesotaAcute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid and Monocytic Leukemia

Start: 2020-02-17End: 2022-09-06Updated: 2023-11-07

Phase 3

Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies

CompletedNCT02566395

Northwell HealthAcute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia +3

Start: 2014-12-31End: 2022-02-14Target: 10Updated: 2022-04-07

Related Papers

A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing.

2011-08-2558 citations